ABOS Earnings Date: Mar 29, 2027 (Estimated) — Acumen Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ABOS's next earnings date?
Acumen Pharmaceuticals, Inc. (ABOS) is expected to report Q4 2026 earnings on Monday, March 29, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.38.
How did ABOS do in its last earnings report?
In its most recent report on Oct 26, 2026 (Q3 2026), Acumen Pharmaceuticals, Inc. posted EPS of -$0.35 versus the -$0.43 estimate, a beat of 18.6%. The stock's 1-day post-earnings move was +14.6%.
How much does ABOS stock move after earnings?
ABOS beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.6% (up or down) in the day after earnings.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
🤖 AI Earnings Analysis
The key catalyst is November 2026 topline data from Phase 2 ALTITUDE-AD, which could materially reshape Acumen’s Alzheimer’s prospects. Q3’s $0.35 loss beat estimates by $0.08, but the clinical readout—not the narrow burn-rate beat—drives the thesis.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-26 | Q3 2026 | -0.43 | -0.35 | +18.60% | — | ✅ Beat | +14.65% | — | — |
| 2026-08-12 | Q2 2026 | -0.40 | -0.45 | -12.50% | $0 | ❌ Miss | +1.62% | +10.93% | +15.79% |
| 2026-08-11 | -0.36 | -0.45 | -25.24% | — | ❌ Miss | +3.29% | +9.46% | +17.28% | |
| 2026-05-12 | Q1 2026 | -0.49 | -0.33 | +32.65% | $0 | ✅ Beat | -3.50% | -15.18% | -12.84% |
| 2026-03-26 | Q4 2025 | -0.53 | -0.41 | +22.64% | $0 | ✅ Beat | -3.04% | -3.04% | -2.28% |
| 2025-11-12 | Q3 2025 | -0.66 | -0.44 | +33.33% | $0 | ✅ Beat | -1.02% | -15.74% | -0.51% |
| 2025-08-12 | Q2 2025 | -0.53 | -0.68 | -28.30% | $0 | ❌ Miss | -11.27% | +0.70% | -4.93% |
| 2025-03-27 | Q4 2024 | -0.37 | -0.62 | -67.57% | $0 | ❌ Miss | +6.03% | -6.90% | -6.90% |
Showing last 8 quarters.